GlassScriptPhysician profile
Mark Allen Gonce
NPI 1295732840
$1,876.89
in general payments reported to CMS, 2019-2025
21 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $117 · 2021: $160 · 2022: $605 · 2023: $188 · 2024: $232 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $573.77 | 2022-2025 | Argos, Hydrus Microstent, Tryptyr |
| Abbvie INC. | $219.61 | 2022-2025 | |
| Allergan, INC. | $180.45 | 2019-2021 | |
| Biotissue Holdings INC. | $164.07 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $108.26 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $92.92 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $90.03 | 2021-2025 | Cequa |
| Bausch & Lomb Americas INC. | $67.85 | 2023-2025 | Xiidra, Miebo |
| Ocular Therapeutix, INC. | $55.04 | 2020-2024 | Dextenza |
| Astellas Pharma US INC | $48.41 | 2024 | Izervay |
| Aerie Pharmaceuticals, INC. | $47.66 | 2019-2021 | |
| Thea Pharma INC. | $40.01 | 2022-2023 | Iyuzeh |
| Shire North American Group INC | $35.87 | 2019 | |
| Boston Scientific Corporation | $26.32 | 2019 | |
| Horizon Therapeutics Plc | $23.33 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $23.33 | 2024 | Iheezo |
| Dompe US, INC. | $17.14 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.06 | 2020 | |
| Oyster Point Pharma, INC. | $16.18 | 2022 | |
| Kala Pharmaceuticals, INC. | $15.26 | 2021 | |
| Sight Sciences, INC. | $14.32 | 2024 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gonce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.